Search Within

Emanuela Ferraro

Formats
  1. Meeting Abstract (15)
  2. Journal Article (10)
  3. Review (7)
  4. Editorial (1)
Groups
  1. Breast Medicine Service (27)
  2. Department of Medicine (27)
  3. Solid Tumor Oncology Division (27)
  4. Survivorship Research (16)
  5. GSK Faculty (13)
  6. Human Oncology and Pathogenesis Program (13)

More Groups

People
  1. Pedram Razavi (13)
  2. Mark Robson (12)
  3. Sarat Chandarlapaty (11)
  4. Shanu Modi (11)
  5. Andrew Seidman (9)
  6. Anton Safonov (9)

More People

Years
  1. 2025 (3)
  2. 2024 (8)
  3. 2023 (7)
  4. 2022 (8)
  5. 2021 (4)
  6. 2020 (3)
Publications
  1. Journal of Clinical Oncology (12)
  2. Cancer Treatment and Research (3)
  3. Annals of Oncology (2)
  4. Cancer Treatment Reviews (2)
  5. European Journal of Cancer (2)
  6. npj Breast Cancer (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (13)
  2. Elsevier Inc. (5)
  3. Springer (4)
  4. Nature Publishing Group (3)
  5. Oxford University Press (2)
  6. AME Publishing Company (1)

More Publishers

Results (33)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of cyclin dependent kinase 4/6 inhibitors on breast cancer brain metastasis outcomes
    Journal Article

    Chew, S. M.; Ferraro, E.; Safonov, A.; Chen, Y.; Kelly, D.; Razavi, P.; Robson, M.; Seidman, A. D.
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Mechanisms of endocrine resistance in hormone receptor-positive breast cancer
    Journal Article

    Marra, A.; Trapani, D.; Ferraro, E.; Curigliano, G.
    Cancer Treatment and Research (2023)

    Fulltext@MSK | Save
  • Innovative therapeutic approaches for patients with HER2-positive breast cancer
    Journal Article

    Taurelli Salimbeni, B.; Ferraro, E.; Boscolo Bielo, L.; Curigliano, G.
    Cancer Treatment and Research (2023)

    Fulltext@MSK | Save
  • Breast cancer brain metastases: Achilles’ heel in breast cancer patients’ care
    Journal Article

    Ferraro, E.; Seidman, A. D.
    Cancer Treatment and Research (2023)

    Fulltext@MSK | Save
  • Prognostic implications of HER2 gain in patients with HR+/ HER2-breast cancer (BC) and TNBC after neoadjuvant chemotherapy (NAC)
    Meeting Abstract

    Ferraro, E.; Chew Minmin, S.; Nemirovsky, D.; Chen, Y.; Barrio, A. V.; Modi, S.; Seidman, A.; Wen, H.; Brogi, E.; Robson, M.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
    Meeting Abstract

    Lazaratos, A. M.; Maritan, S. M.; Darlix, A.; Ratosa, I.; Ferraro, E.; Griguolo, G.; Pellerino, A.; Hofer, S.; Jacot, W.; Stemmler, H. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab
    Meeting Abstract

    Chew, S.; Ferraro, E.; Chen, Y.; Barrio, A. V.; Kelly, D. W.; Modi, S.; Seidman, A. D.; Wen, H. Y.; Brogi, E.; Robson, M. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
    Review

    Lazaratos, A. M.; Maritan, S. M.; Quaiattini, A.; Darlix, A.; Ratosa, I.; Ferraro, E.; Griguolo, G.; Guarneri, V.; Pellerino, A.; Hofer, S.; more...
    Breast (2023)

    Fulltext@MSK | Save
  • Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)
    Meeting Abstract

    Marra, A.; Gazzo, A.; Gupta, A.; Selenica, P.; Da Silva, E. M.; Pareja, F.; Pei, X.; Zhu, Y.; Razavi, P.; Safonov, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer
    Meeting Abstract

    Safonov, A. M.; Bandlamudi, C.; Selenica, P.; Marra, A.; Ferraro, E.; Mandelker, D.; Solit, D. B.; Berger, M. F.; Norton, L.; Powell, S. N.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save